Chugai Pharmaceutical (OTCMKTS:CHGCY) Shares Gap Up – Here’s What Happened

Shares of Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) gapped up before the market opened on Thursday. The stock had previously closed at $19.24, but opened at $20.62. Chugai Pharmaceutical shares last traded at $19.8750, with a volume of 91,313 shares changing hands.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on CHGCY shares. UBS Group lowered shares of Chugai Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 6th. Nomura raised shares of Chugai Pharmaceutical to a “hold” rating in a research report on Tuesday, September 1st. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy”.

Chugai Pharmaceutical Stock Up 4.0%

The company has a fifty day simple moving average of $20.96 and a 200 day simple moving average of $23.21. The firm has a market capitalization of $65.88 billion, a P/E ratio of 21.76 and a beta of 0.60.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last issued its quarterly earnings results on Friday, July 24th. The company reported $0.22 earnings per share for the quarter. The firm had revenue of $2.14 billion during the quarter, compared to the consensus estimate of $2.38 billion. Chugai Pharmaceutical had a return on equity of 23.76% and a net margin of 35.09%. As a group, equities analysts expect that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.96 earnings per share for the current fiscal year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd. is a Japan-based research-driven pharmaceutical company that develops, manufactures and markets prescription medicines. Its research focuses on oncology, immunology, neuroscience, hematology and other areas of significant unmet medical need, with capabilities spanning drug discovery, clinical development, manufacturing and commercialization.

Chugai’s portfolio includes medicines such as Actemra (tocilizumab), an immunology treatment; Hemlibra (emicizumab), used to prevent bleeding in people with hemophilia A; and Alecensa (alectinib), a targeted therapy for certain forms of lung cancer.